Dijon, France – April 13th, 2026 – Oncodesign Services has extended its collaboration with GIP ARRONAX to secure access to astatine-211 (At-211) as well as other radionuclides used in targeted radiotherapy (TRT), supporting the advancement of discovery and preclinical programs.
The collaboration builds on an existing relationship between the two organizations and focuses on securing the supply of radionuclides that remain difficult to access at scale. This is particularly relevant for astatine-211, an alpha-emitting radioisotope which is the subject of increasing scientific interest but has limited availability due to production and logistical constraints.
GIP ARRONAX, a French research institute specialising in the development and production of innovative radionuclides, already supplies lead-203 (Pb-203) and copper-64 (Cu-64) to Oncodesign Services. The extended collaboration now includes astatine-211, enabling continued access for programs requiring this isotope.
“Astatine-211 is attracting attention due to its favourable nuclear properties and potential application in targeted radiotherapy,” said Dr. Aidan Synnott, CEO, Oncodesign Services. “However, its short half-life and limited production capacity make access and logistics critical. Extending our collaboration with GIP ARRONAX helps address these constraints and supports continuity in preclinical programs.”
Astatine-211 has a half-life of approximately seven hours, meaning that production, transport and study execution must be tightly coordinated. Securing access to such radionuclides is a prerequisite for generating robust and interpretable preclinical data in TRT programs.
Oncodesign Services is a preclinical research services provider focused on translational drug development, with expertise in oncology, radiopharmaceuticals, immuno-oncology and inflammation. Its work in targeted radiotherapy spans early candidate evaluation through to IND-enabling studies, addressing key challenges including radionuclide supply, biodistribution, dosing strategy and translational relevance.
The company’s approach centres on aligning study design with clinical intent, ensuring that data generated at the preclinical stage can meaningfully inform downstream choices and investment / funding decisions. This includes careful consideration of model selection, endpoints and the limitations of available evidence.
“We have been working with astatine-211 for many years, producing it on a very regular basis and supporting its transition to GMP production and clinical trials”, said Pr. Ferid Haddad, GIP ARRONAX Director. “Our experience covers the full development chain from isotope production to radiolabeling scale-up and IMPD preparation and clinical dose delivery, partnering with several companies developing next generation alpha emitter therapies.”
The extended collaboration reflects a shared focus on enabling translational research in a field where scientific, logistical and operational factors are closely interconnected. It also supports Oncodesign Services’ broader objective of reducing delays in development by addressing bottlenecks early in the preclinical phase.
Oncodesign Services will present its targeted radiotherapy capabilities at upcoming scientific meetings, including the American Association for Cancer Research (AACR) Annual Meeting and the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting.
About Oncodesign Services:
Oncodesign Services is a preclinical CRO specialized in oncology, radiopharmaceuticals, and immune-mediated diseases. With recognized expertise in early-stage targeted radiotherapy programs, and leveraging advanced capabilities in in vivo pharmacology and preclinical imaging, the company generates robust efficacy and translational data to support confident progression towards the clinic.
About GIP ARRONAX:
GIP ARRONAX is a public research institute grouping several public members, large national research organizations, higher education and research institutions and hospitals. GIP ARRONAX develops and produces innovative radionuclides for nuclear medicine, with a 14-years-long expertise in the production and labeling of astatine-211, and performs research in radiochemistry and radiolysis. GIP ARRONAX also manufactures radiopharmaceuticals to GMP standards to support early-stage clinical research.
Media Contact: Aranda Rahbarkouhi
ramarketing
aranda@ramarketingpr.com
+44 7807 009 347
Liz Hudson
Oncodesign Services
comms@oncodesign-services.com
+33 3 80 78 82 60
Tony Prézeau
GIP Arronax
prezeau@arronax-nantes.fr / contact@arronax-nantes.fr
